Background & Aims Non-alcoholic fatty liver disease (NAFLD) is very common in the general
population, but identifying patients with increased risk of mortality and liver-specific morbidity
remains a challenge. Non-alcoholic steatohepatitis (NASH) is thought to enhance this risk;
therefore, resolution of NASH is a major endpoint in current pharmacologic studies. Herein,
we aim to investigate the long-term prognosis of a large cohort of NAFLD patients, and to
study the specific effect of NASH and fibrosis stage on prognosis. Methods We conducted a …